use of entericcoated mycophenolate sodium in de novo renal transplant recipients with high incidence of delayed graft function patients with delayed graft function dgf are at risk of increased incidence for acute rejection episodes are mycophenolate mofetil or induction therapy has produced a reduction in are incidence an open prospective 3month trial was performed in a group of argentinian renal transplant recipients we recruited 46 patients 717 men aged 417 138 years including 36 783 recipients of cadaveric donors cd who were aged 434 155 years with a cold ischemia time of 194 hours 54 minutes and 10 277 recipients of living donors ld aged 378 129 years hla mismatches or 3 were observed in 584 of cd and in 7 of ld all patients received two doses of basiliximab 20 mg each days 0 and 4 cyclosporine microemulsion csame monitored by the secondhour concentrations c2 entericcoated mycophenolate sodium ecmps 720 mg twice a day and steroids a 58 incidence of dgf was observed at the end of the third month the incidence of biopsyproven are was 15 with a median serum creatinine of was 154 042 mgdl including three grafts lost two patients died no patient required ecmps dose discontinuation but 20 of patients required dose adjustments the absence of discontinuations and the low incidence of dose adjustments of ecmps in this highrisk de novo population provided support of a suitable tolerability profile for this ecmps and the possibility to impact efficacy results